Last reviewed · How we verify

Enalapril and carvedilol — Competitive Intelligence Brief

Enalapril and carvedilol (Enalapril and carvedilol) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ACE inhibitor and beta-blocker combination. Area: Cardiovascular.

phase 3 ACE inhibitor and beta-blocker combination ACE (angiotensin-converting enzyme) and beta-adrenergic receptors Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Enalapril and carvedilol (Enalapril and carvedilol) — Hospital Clinic of Barcelona. This combination reduces blood pressure and heart workload by blocking angiotensin II formation (enalapril) and beta-adrenergic signaling (carvedilol).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Enalapril and carvedilol TARGET Enalapril and carvedilol Hospital Clinic of Barcelona phase 3 ACE inhibitor and beta-blocker combination ACE (angiotensin-converting enzyme) and beta-adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ACE inhibitor and beta-blocker combination class)

  1. Hospital Clinic of Barcelona · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Enalapril and carvedilol — Competitive Intelligence Brief. https://druglandscape.com/ci/enalapril-and-carvedilol. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: